PeptideInfo
العربيةGet the app
☰
Cognitive aging researchNot approved (US)

Pinealon

EDR Peptide

Pinealon is investigated for increasing cell viability through reduced free-radical activity and increased proliferation. Research on the EDR peptide also examines gene-expression and protein-synthesis regulation in Alzheimer’s disease. These proposed mechanisms do not establish a clinical benefit.

Not medical advice. Educational reference only.

Route
Subcutaneous injection (preparation guidance); protocol routes vary
Storage
Keep refrigerated at 2–8°C and use within 28 days.

What is Pinealon?

Pinealon is a Russian peptide bioregulator investigated for signaling associated with cognition and aging. Its potential applications include preservation of cognitive function and cellular changes during aging. It has no FDA approval.

Mechanism of action

Pinealon is investigated for increasing cell viability through reduced free-radical activity and increased proliferation. Research on the EDR peptide also examines gene-expression and protein-synthesis regulation in Alzheimer’s disease. These proposed mechanisms do not establish a clinical benefit.

Research indications

  • Cellular Longevity

    Moderate

    Investigations address telomere length and the development of cellular senescence.

  • Hormonal Balance

    Moderate

    Potential hormonal effects concern changes that occur with advancing age.

  • Cognitive Aging

    Limited

    Early investigations consider preservation of cognitive abilities during aging.

Interactions

  • Medications

    Caution

    Consult your prescriber before combining this compound with any medication.

  • BPC-157

    Compatible

  • NAD+

    Compatible

  • Vitamin D

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water; avoid saline because it may cause precipitation.

  1. Let your refrigerated Pinealon vial warm to room temperature for 15–20 minutes before preparation.
  2. Disinfect the vial’s rubber closure with an alcohol wipe, then wait until it has dried completely.
  3. Use a sterile syringe to measure the calculated amount of bacteriostatic water. Avoid saline because precipitation may occur.
  4. Add the water slowly against the vial’s inner wall. Keep the stream away from the dry powder itself.
  5. Rotate the vial gently to mix its contents. Do not shake forcefully, because this can damage the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
  7. Measure your calculated subcutaneous dose with an insulin syringe after dissolution.
  8. Choose the abdomen, upper arm or thigh for injection. Alternate the injection location each time to help prevent lipodystrophy.
  9. Refrigerate the mixed solution at 2–8°C, and discard any remainder after 28 days. Use these steps only for an appropriate research formulation; follow the specific product instructions for prescription presentations.

What to expect

Week 1–2
An early adjustment period may accompany initial effects. Watch for adverse reactions while assessing tolerance.
Week 2–4
The main effects may begin to emerge. Change the dose only in accordance with your clinician’s recommendations.
Week 4–8
The intended effects may become established during this interval. Review your progress together with your clinician.
Week 8+
Reassess the outcome and discuss whether to continue, introduce a cycle break or change the dose. These research expectations do not establish individual treatment outcomes.

Side effects and safety

  • Local redness, bruising or mild pain after an injection
  • Possible allergic reactions, including rash or hives; stop use if these develop
  • Responses vary by person; use only the lowest clinician-directed amount, monitor carefully and report unusual symptoms

Pinealon: not approved in the US.

Regulatory status

  • US

    Not approved

    FDA — No US approval. Research use does not constitute approval for treatment in humans.

    Rx required
    No
    Telehealth
    N/A

Frequently asked questions

Which dosing approaches are discussed?

The starting research approach uses a low dose, followed by titration for the standard approach. Neither approach defines a numeric amount. Frequency depends on the particular protocol, and the route varies; these descriptions therefore do not establish a dosing regimen. Discuss any use with a qualified clinician rather than selecting an amount from these qualitative terms.

References

  1. Peptide bioregulators: a new class of geroprotectors (2006)

  2. Peptide bioregulation of aging: results and prospects. (2010)

    PMID 19830585DOI 10.1007/s10522-009-9249-8

  3. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. (2011)

    PMID 21978084DOI 10.1089/rej.2011.1172

  4. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. (2020)

    PMID 33396470DOI 10.3390/molecules26010159